Analyst William Pickering of Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $502.00. William Pickering has given his Hold rating due
Analyst William Pickering of Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $502.00. William Pickering has given his Hold rating due
Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals to $474 from $462 and keeps an Equal Weight rating on the shares. Suzetrigine, or VX-548, is being studied for
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $474.00. Terence Flynn has given his Hold
In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $515.00. The company’s shares
Pfizer (